Diverticular disease

Global Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast Report to 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Genetics, Pharmaceutical, Health, Arachnoid, Epidemiology, Cyst, Hypertension, Colin L. Masters, Doctor of Philosophy, ERM, PKD2, Growth, Population, Diagnosis, Mitral valve prolapse, Kidney failure, Patient, Urinary tract infection, Degenerative disease, Renal cysts and diabetes syndrome, Kidney, Diverticular disease, Polycystic kidney disease, Hernia, Stabat Mater, Hematuria, Adult, Liver, United Kingdom, Fibrosis, PKD1, Master's degree, Intracranial aneurysm, Autosome, Left ventricular hypertrophy, Chronic kidney disease, Pancreas, Autosomal dominant polycystic kidney disease, PKD, Vaccine, Pharmaceutical industry, Lithium, Medical device, Health insurance, Management

The "Autosomal Dominant Polycystic Kidney Disease - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autosomal Dominant Polycystic Kidney Disease - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as Autosomal Dominant Polycystic Kidney Disease trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease are likely to change by 2032 in the forecast period 2022-2032.
  • The report provides the segmentation of the disease epidemiology for the 7MM, a total number of total Diagnosed Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease, Age-specific cases of Autosomal Dominant Polycystic Kidney Disease, and Mutation-specific cases of Autosomal Dominant Polycystic Kidney Disease.

NYU LANGONE HEALTH EXPANDS ACCESS TO HIGH-QUALITY OUTPATIENT CARE IN SUFFOLK COUNTY

Retrieved on: 
Thursday, October 6, 2022
Physician, COPD, Growth, Education, NYU, Patient, Gastroenterology, Hospital Road, GI, Lung cancer, IBS, Diverticular disease, MD, Irritable bowel syndrome, NYU Langone Health, Patient safety, GERD, Stony Brook Southampton Hospital, Respiratory disease, Chronic obstructive pulmonary disease, Gastroesophageal reflux disease, Hospital, Medicine

Expanding its gastroenterology (GI) network on Long Island, NYU Langone recently welcomed Steve Georgopoulos, MD , clinical assistant professor of medicine at NYU Long Island School of Medicine, who sees patients at NYU Langone Medical AssociatesRiverhead and NYU Langone Medical AssociatesBridgehampton.

Key Points: 
  • Expanding its gastroenterology (GI) network on Long Island, NYU Langone recently welcomed Steve Georgopoulos, MD , clinical assistant professor of medicine at NYU Long Island School of Medicine, who sees patients at NYU Langone Medical AssociatesRiverhead and NYU Langone Medical AssociatesBridgehampton.
  • Before joining NYU Langone, Dr. Georgopoulos was the former chief of gastrointestinal endoscopy at Stony Brook Southampton Hospital.
  • NYU Langone also added GI services at NYU Langone Medical AssociatesPatchogue, 100 Hospital Road, welcoming Chris E. Lascarides, MD , clinical associate professor of medicine at NYU Long Island School of Medicine and clinical director for ambulatory gastroenterology in Suffolk County.
  • The multilingual care team at NYU Langone Pulmonary AssociatesEast Patchogue , formerly Suffolk Chest Physicians, offers comprehensive diagnostic testing and care for pulmonary conditions.

Global Gastrointestinal Drugs Market Report 2022: Focus on Antacids, Antiulcerants, Antiobesity, Antiemetics and Antinauseants, & Antidiarrhoeals - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022
Health, Pharmaceutical, Proton, Joint Medical Service (Germany), Reckitt, Constipation, Irritable bowel syndrome, Population, Ageing, Antiemetic, Daiichi Sankyo, Ulcerative colitis, Rockies Express Pipeline, Degenerative disease, Sucralfate, Proton-pump inhibitor, Antibody, Diverticular disease, Bayer, Route of administration, COVID-19, Prescription drug purchasing pool, Patent, Johnson & Johnson, Inflammatory bowel disease, Peptide, Procter & Gamble, WHO, Anal fissure, Hemorrhoid, Antacid, Heartburn, Organization, Eli Lilly, Takeda Pharmaceutical Company, Proton pump, Protein, Antidiarrhoeal, CAGR, Growth, Abbott Laboratories, Gastrointestinal tract, Fine chemical, Dietary supplement, Pharmaceutical industry, Misoprostol

The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.

Key Points: 
  • The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.
  • The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
  • The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals.
  • During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs.

Solera Health Launches Digestive Health Offering with Best-in-Class Digital Therapy Solutions: Oshi Health and Vivante Health

Retrieved on: 
Monday, March 28, 2022
Degenerative disease, Cancer, Life, Health, Diverticular disease, Functional constipation, Mental health, IBS, Diagnosis, ER, Autoimmunity, Common, GERD, Program, Gastroesophageal reflux disease, CEO, Prevalence, GI, Quality of life, Irritable bowel syndrome, Industry, Hemorrhoid, Mental, Inflammatory bowel disease, Disorder, Esophageal motility disorder, Human musculoskeletal system, Solution, Intracellular digestion, Patient, Partnership, Health insurance, Oshi, PHOENIX, Solera

PHOENIX , March 28, 2022 /PRNewswire/ -- Solera Health, the premier platform for connecting people seamlessly and easily to health solutions that work, announces the launch of its new Digestive Health offering with leading digital therapy solutions: Oshi Health and Vivante Health. These new network partners continue Solera's strategy of bringing programs that address the diverse clinical needs of their payer and employer member populations. All network partners were carefully selected after an extensive vetting process to ensure that they met Solera's high standards for efficacy and customer satisfaction. With Solera's unique value-based payment model, payers and employers get high-quality solutions focused on engagement and industry benchmarked outcomes.

Key Points: 
  • "Digestive Health diseases affect nearly one in five Americans and cost more than $140B per year in direct and indirect costs to employers and health plans," said Mary Langowski, CEO, Solera Health.
  • Oshi Health has redesigned digestive health care around what patients really need and want: convenient, supportive care that quickly achieves sustainable symptom control.
  • Our all-in-one digestive health program, GIThrive, empowers peoplethrough innovative technology, advanced science, and on-demand human supportto improve digestive health, while lowering their cost of care.
  • Vivante Health provides positive patient outcomes at scale for large employers, including multiple fortune 500 companies and leading health plans.

RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans

Retrieved on: 
Wednesday, December 1, 2021
Patient, Clarithromycin, Ketoconazole, Anxiety, Diverticulitis, Brain, OIC, Nausea, Chills, Medicare, Multiple sclerosis, Cancer, Traffic barrier, PAMORA, Headache, GI, Flatulence, Alzheimer's disease, Abdominal pain, Chronic pain, Obstruction, Ischemic colitis, Nasdaq, Risk, Hyperhidrosis, Diarrhea, Adult, Irritability, Yawn, Methadone, Medicare Part D, Formulary, CYP3A4, Vomiting, TEL, Redhill, Opioid, Excipient, Diverticular disease, Bevacizumab, Analgesic, Epilepsy, Pharmaceutical industry

"This important new listing for Movantik, the market-leading PAMORA for opioid-induced constipation, as a preferred and unrestricted brand on a major National Medicare Part D formulary provides that access to more than 10 million more Americans covered by this formulary.

Key Points: 
  • "This important new listing for Movantik, the market-leading PAMORA for opioid-induced constipation, as a preferred and unrestricted brand on a major National Medicare Part D formulary provides that access to more than 10 million more Americans covered by this formulary.
  • Patients with known or suspected gastrointestinal (GI) obstruction and patients at risk of recurrent obstruction, due to the potential for GI perforation.
  • Patients with a known serious or severe hypersensitivity reaction to Movantik or any of its excipients.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

Retrieved on: 
Tuesday, September 7, 2021

said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.

Key Points: 
  • said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.
  • "There has been a shift in clinical practice to try to reduce doses of opioids used to treat chronic pain.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.
  • You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at1-833-ADRHILL(1-833-237-4455)or FDA at1-800-FDA-1088or www.fda.gov/medwatch .

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

Retrieved on: 
Tuesday, September 7, 2021

TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation at PAINWeek 2021 of three new analyses of Movantik® (naloxegol) Phase 3 study data demonstrating rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged ≥ 65 and across both low and high dose opioid therapy.

Key Points: 
  • said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.
  • "There has been a shift in clinical practice to try to reduce doses of opioids used to treat chronic pain.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.
  • You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at1-833-ADRHILL(1-833-237-4455)or FDA at1-800-FDA-1088or www.fda.gov/medwatch .

Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial

Retrieved on: 
Wednesday, August 5, 2020
Medical specialties, Clinical medicine, Medicine, Large intestine, Diverticulosis, Diverticulum, Colon cleansing, Diverticular disease, Segmental colitis associated with diverticulosis

While the pilot study is still ongoing, Emmaus will be preparing for a Phase 3 trial to assess the efficacy and safety of PGLG in the treatment of diverticulosis.

Key Points: 
  • While the pilot study is still ongoing, Emmaus will be preparing for a Phase 3 trial to assess the efficacy and safety of PGLG in the treatment of diverticulosis.
  • Diverticulosis, or the presence of colonic diverticula (i.e., pouches in the colon wall), is very common in industrialized nations.
  • An estimated 40% of 60 year-olds and 70% of 80 year-olds in the U.S. have diverticulosis.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.